ClinicalTrials.gg
RecruitingNCT07454720Updated May 5, 2026

A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer

A Phase 2/3 interventional study of Adebrelimab in combination with SHR-8068 and chemotherapy and Adebrelimab combined with chemotherapy in Locally Advanced Resectable Rectal Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 462 studies in Rectal Neoplasms with a site in China — 227 open to participants now, 266 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
128th of 372
165 · median 100
Started
2026
with 49 others
Phase 2/3
15 of 462
9 open now
Primary completion
2032-11
later than 265 of 265 live
Registered
413th of 462
by date

Among the 462 studies in Rectal Neoplasms with a site in China, this one is the 128th largest by planned enrollment of the 372 interventional ones that give a count, is one of 50 that started in 2026, is one of 15 in phase 2/3, reaches primary completion later than 265 of the 265 other live ones, and was the 413th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

227 of the 462 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

221 more — sign in →

All 227 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 462 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.

03

Conditions studied

  • Locally Advanced Resectable Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. Male or female ≥ 18 years old and ≤75 years old.
  3. performance status of 0-1.
  4. An assessment of resectable locally advanced rectal.
  5. Has not received any anti-tumor treatment for rectal cancer.
  6. With a of ≥2 years.
  7. Male participants whose partners are fertile women and fertile female participants must take effective measures together with their partners from the time of signing the informed consent form until 6 months after the last administration of the drug or the last radiotherapy. Female participants with fertility must have a negative serum or urine test for human chorionic gonadotropin (HCG) within 7 days before the first administration of the drug (if the serum HCG test is positive, pregnancy should be ruled out and further discussion with the sponsor should be conducted), and they must be not in the lactation period.

Exclusion criteria

Exclusion Criteria:

  1. Patients with rectal cancer who have experienced local recurrence after previous treatment.
  2. Patients with concurrent colon tumors.
  3. Patients with initially unresectable colorectal cancer as evaluated by researchers or those whose condition is determined by researchers to be intolerant to surgery.
  4. Clinical or imaging examinations suggest the presence of intestinal obstruction or perforation, or those assessed by researchers as having a relatively high risk of perforation or bleeding.
  5. With distant .
  6. Imaging examination of rectal cancer indicated positive lateral lymph nodes.
  7. Having received surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. for tumors.
  8. Female participants who are pregnant, breastfeeding or planning to become pregnant during the study period.
  9. There are uncontrollable mental illnesses and other circumstances known to affect the completion of the research procedures, such as alcohol abuse, drug abuse or drug abuse, and criminal detention.
  10. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Patients will receive radiotherapy and Adebrelimab in combination with SHR-8068 and chemotherapy as perioperative treatment.

    Drug: Adebrelimab in combination with SHR-8068 and chemotherapy

  • Experimental
    Cohort 2

    Patients will receive radiotherapy and Adebrelimab combined with chemotherapy as perioperative treatment.

    Drug: Adebrelimab combined with chemotherapy

  • Experimental
    Cohort 3

    Patients will receive radiotherapy plus chemotherapy as perioperative treatment.

    Drug: Chemotherapy

Interventions

  • DrugAdebrelimab in combination with SHR-8068 and chemotherapy

    Drug pages: Adebrelimab · Anti-CTLA-4 Monoclonal Antibody SHR-8068

    Adebrelimab in combination with SHR-8068 and chemotherapy.

  • DrugAdebrelimab combined with chemotherapy

    Drug page: Adebrelimab

    Adebrelimab combined with chemotherapy.

  • DrugChemotherapy

    Chemotherapy.

06

What researchers measure

Primary outcomes

  1. Phase II: pCR (Pathological Complete Response) rate

    Evaluated by investigators.

    Time frame: 12 months

Secondary outcomes

  1. Phase II: Clinical complete response (cCR) rate

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  2. Phase II: Disease-free survival (DFS)

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  3. Phase II: EFS (Event Free Survival)

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  4. Phase II: Tumor regression grade (TRG)

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  5. Phase II: R0 resection rate

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  6. Phase II: length of hospital stay

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  7. Phase II: Overall survival (OS)

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

  8. Phase II: Perioperative mortality (within 30 days and 90 days after surgery)

    Evaluated by investigators per RECIST v1.1.

    Time frame: 60 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Nov 2032, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 6, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Nov 2032
CompletionEst.
Nov 2035
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454720
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 23, 2026
Primary completion
Nov 2032 (estimated)
Completion
Nov 2035 (estimated)
Last update
May 5, 2026

Study contacts

Chuanpei Huang
Contact
chuanpei.huang@hengrui.com
+86-021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Anti-CTLA-4 Monoclonal Antibody SHR-8068

Start the discussion